TransMedics Group (TMDX) Set to Announce Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The business had revenue of $81.20 million during the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s revenue was up 158.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) EPS. On average, analysts expect TransMedics Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $92.08 on Friday. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of -119.58 and a beta of 1.99. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The company has a 50-day simple moving average of $82.98 and a 200 day simple moving average of $74.69. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $99.63.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the sale, the director now directly owns 8,350 shares of the company’s stock, valued at approximately $721,273. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total transaction of $618,221.66. Following the sale, the director now directly owns 8,350 shares of the company’s stock, valued at approximately $721,273. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James R. Tobin sold 13,380 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $83.63, for a total transaction of $1,118,969.40. Following the sale, the director now directly owns 220,211 shares in the company, valued at $18,416,245.93. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,078 shares of company stock valued at $9,972,971. 6.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Morgan Stanley lifted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Piper Sandler initiated coverage on shares of TransMedics Group in a research note on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price objective for the company. Finally, Oppenheimer boosted their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.